• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Natan David claimed no ownership of stock in the company

    2/18/22 3:25:51 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SBFM alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    NATAN DAVID

    (Last) (First) (Middle)
    C/O SUNSHINE BIOPHARMA, INC.
    6500 TRANS-CANADA HIGHWAY-4TH FLOOR

    (Street)
    POINTE-CLAIRE A8 H9R0A5

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/10/2022
    3. Issuer Name and Ticker or Trading Symbol
    Sunshine Biopharma, Inc [ SBFM ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 0 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ David Natan 02/18/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SBFM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBFM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SBFM
    Leadership Updates

    Live Leadership Updates

    See more
    • Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

      FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutic

      1/15/25 8:00:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SBFM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

      SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

      11/14/24 4:28:14 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sunshine Biopharma Inc.

      SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)

      2/23/24 4:03:01 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sunshine Biopharma Inc.

      SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)

      2/21/24 4:28:39 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SBFM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SBFM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SBFM
    Financials

    Live finance-specific insights

    See more

    $SBFM
    SEC Filings

    See more

    $SBFM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Roy Michel claimed ownership of 1 shares (SEC Form 3)

      3 - Sunshine Biopharma Inc. (0001402328) (Issuer)

      1/21/25 8:20:21 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

      4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

      3/5/24 4:05:35 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slilaty Steve N. bought $2,000 worth of Series B Preferred Stock (20,000 units at $0.10), increasing direct ownership by 200% to 30,000 units (SEC Form 4)

      4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

      2/12/24 4:05:15 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

      FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs.The newly launched drugs are Olanzapine and Olanzapine ODT. Olanzapine is a generic version of Zyprexa®. Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders. Olanzapine is also indicated for the acute treatment of manic or mixed episodes of bipolar I disorder.

      1/21/25 8:00:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

      FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutic

      1/15/25 8:00:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

      FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has developed an orally active protease inhibitor with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2).There are still unmet medical needs for agents to combat SARS-CoV-2 infections. SARS-CoV-2 is the etiologic agent of COVID-19 and one of three types of Coronavirus that cause Severe Acute Respiratory Syndrome (SARS). SARS-CoV-2 undergoes mutation at a rapid rate, which leads to the con

      12/9/24 7:30:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

      MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. As such, Nora Pharma Inc. is now a wholly owned subsidiary of Sunshine Biopharma Inc. Nora Pharma is one of North America's fastest growing generic pharmaceuticals companies. The addition of Nora Pharma allows Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars. The purchase price of $30,000,000 Canadian (approxi

      10/20/22 8:00:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sunshine Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

      5/19/25 5:06:14 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Sunshine Biopharma Inc.

      10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)

      5/15/25 4:06:03 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Sunshine Biopharma Inc.

      SCHEDULE 13G - Sunshine Biopharma Inc. (0001402328) (Subject)

      4/11/25 5:02:07 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

      4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

      3/5/24 4:05:35 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slilaty Steve N. bought $2,000 worth of Series B Preferred Stock (20,000 units at $0.10), increasing direct ownership by 200% to 30,000 units (SEC Form 4)

      4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

      2/12/24 4:05:15 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care